Population Pharmacokinetic Modeling of Posaconazole in Japanese Patients Receiving Fungal Prophylaxis.

Mitsuhiro SugimotoAtsushi YonezawaJunya KandaKotaro ItoharaDaiki HiraTakeo YamagiwaRisa TaniguchiYuta HanyuMizuki WatanabeYasuyuki AraiChisaki MizumotoToshio KitawakiTadakazu KondoKouhei YamashitaAkifumi Takaori-KondoTomohiro Terada

Published in: Therapeutic drug monitoring (2024)

PopPK analysis revealed that HSCT, diarrhea, and aspartate aminotransferase were factors associated with the CL/F of posaconazole. The trough concentration of posaconazole may be below the therapeutic range in a few patients with diarrhea and/or after HSCT. As invasive fungal infections in patients with hematologic diseases can be life-threatening, therapeutic drug monitoring of posaconazole is strongly recommended, and patients should be carefully monitored.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
prognostic factors
irritable bowel syndrome
peritoneal dialysis
clostridium difficile
single cell
patient reported